(New York Post) Singer, while getting cold feet at $160 per share, could be mulling a bid at a lower price, sources said. At the same time, other suitors — including some strategic companies that had made initial inquiries — have also gone quiet,
Paul Singer balks at $160 per share Athenahealth bid
This entry was posted in Syndicated. Bookmark the permalink.
